Crystagen and Vilon Interaction: Synergistic | Peptide Database

Normalizes immunogram in elderly patients with impaired immunity. Restores immune function after infectious diseases. Helps normalize immunity after radiation and chemotherapy exposure. Increases stress resistance and reduces respiratory infections in athletes. Doubles expression of heat-shock protein gene HSPA1A. Inhibits proliferation of K-562 human erythromyelosis tumor cells.

Join others researching MENT — share findings, ask questions, and learn from real experiences MENT (7-alpha-methyl-19-nortestosterone), also known as trestolone, is an experimental synthetic anabolic-androgenic steroid that belongs to the 19-nor (nandrolone) family. It was originally developed by the Population Council as a potential male hormonal contraceptive and androgen replacement therapy. MENT is estimated to be roughly 10 times more potent than testosterone on a milligram-per-milligram basis, which allows for effective use at very low doses. Unlike nandrolone, MENT does not cause the characteristic sexual dysfunction ('deca dick') associated with other 19-nor compounds, because it maintains sufficient androgenic activity in the central nervous system and sexual tissues. This property has generated significant interest in MENT as a potential standalone replacement for testosterone -- a compound that could serve as both the anabolic and androgenic base in hormone replacement protocols. MENT aromatizes, but its aromatization product is 7-alpha-methyl-estradiol rather than standard estradiol. This methylated estrogen behaves differently from estradiol in some respects, and aromatase inhibitors like anastrozole have reduced efficacy against it. Estrogen management on MENT is therefore considered more challenging than with testosterone. The acetate ester is the most widely available formulation and has an extremely short half-life of approximately 40 minutes, necessitating daily or twice-daily injections for stable blood levels. Research into longer-acting esters and delivery systems (including subdermal implants) is ongoing. MENT remains an investigational compound with no current FDA approval, though Phase 2 clinical trials for male contraception have been conducted. MENT binds to the androgen receptor with high affinity, estimated at roughly 10 times the potency of testosterone, driving robust activation of AR-dependent gene transcription pathways responsible for protein synthesis, nitrogen retention, and satellite cell proliferation in skeletal muscle. Its 7-alpha methyl group renders it resistant to 5-alpha reductase, meaning it is not converted to a reduced metabolite in androgen-sensitive tissues the way testosterone is converted to DHT or nandrolone is converted to DHN. MENT itself acts directly on androgen receptors throughout the body, including the brain, prostate, and sexual tissues, which is why it maintains libido and sexual function unlike nandrolone. MENT aromatizes via the aromatase enzyme, but the product is 7-alpha-methyl-estradiol rather than estradiol. This methylated estrogen retains estrogenic activity and binds to estrogen receptors, but conventional aromatase inhibitors (anastrozole, letrozole) have diminished ability to block its formation. The mechanism behind this reduced AI efficacy appears related to the 7-alpha methyl group altering the substrate's interaction with the aromatase active site. MENT powerfully suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing LH and FSH to near-undetectable levels at relatively low doses. This profound gonadotropin suppression is the basis for its investigation as a male contraceptive, as it can reduce sperm production to azoospermia or severe oligospermia in most men. Despite its 19-nor classification, MENT does not appear to have the significant progestogenic activity that nandrolone exhibits, though some degree of progesterone receptor interaction has been reported in preclinical studies.